VITILIGO KASALLIGINI DAVOLASHDA SOG‘LOM TERI AUTOTRANSPLANTATSIYASI VA STANDART TERAPIYA USULLARINING QIYOSIY TAHLILI HAMDA DAVOLASHNI OPTIMALLASHTIRISH
Keywords:
vitiligo, melanotsit, autotransplantatsiya, melanotsit-keratinotsit transplantatsiyasi (MKTP), teri grefti, tor diapazonli UVB fototerapiya, ruksolitinib, repigmentatsiya, davolashni optimallashtirish.Abstract
Vitiligo — melanotsitlarning immun-mediator mexanizm orqali nobud bo‘lishi natijasida teri va shilliq qavatlarda depigmentlangan (sutdek oq) dog‘lar paydo bo‘lishi bilan kechadigan surunkali autoimmun dermatoz hisoblanadi. Kasallik dunyo aholisining taxminan 0,5–2 foizida uchraydi, istalgan yoshda boshlanishi mumkin, biroq ko‘pincha 10–30 yoshlarda namoyon bo‘ladi va jinsga bog‘liq emas. Klinik kechishi bo‘yicha segmentar bo‘lmagan (generalizatsiyalangan) va segmentar shakllar farqlanadi. So‘nggi yillardagi tadqiqotlar kasallik patogenezida interferon-gamma (IFN-γ)–JAK–STAT signal yo‘lining markaziy o‘rin tutishini ko‘rsatdi: bu yo‘l sitotoksik CD8⁺ T-limfotsitlarni jalb qilib, CXCL10 kabi xemokinlar ishlab chiqarilishi va melanotsitlar apoptozini kuchaytiradi [1]. Etiopatogenezda autoimmun mexanizm bilan birga oksidlovchi stress, genetik moyillik va neyrogen omillar ham ishtirok etadi; vitiligo ko‘pincha qalqonsimon bez patologiyasi va boshqa autoimmun kasalliklar bilan birga uchraydi. Ko‘rinadigan sohalarda joylashganligi sababli kasallik bemorning ruhiy holati, hayot sifati va ijtimoiy moslashuviga sezilarli salbiy ta’sir ko‘rsatadi
References
Efficacy of Janus kinase inhibitor combined with phototherapy in non-segmental vitiligo: systematic review and meta-analysis. PMC12777791.
Tavoletti G., et al. Topical ruxolitinib: a new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023. doi:10.1111/jdv.19162.
Yousefian F., et al. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo. J Cosmet Dermatol. 2023. doi:10.1111/jocd.15537.
Current status of cell-based therapies for vitiligo: a review of clinical studies (2000–2022). PMC9964504.
Jafarzadeh A., Pour Mohammad A., Goodarzi A. A systematic review of case series and clinical trials investigating regenerative medicine for the treatment of vitiligo. J Cosmet Dermatol. 2024. doi:10.1111/jocd.16660.
Shahbazi A., Abedi Valugerdi M., Kazemi S., et al. Safety and efficacy of autologous melanocyte/keratinocyte transplantation in patients with refractory stable vitiligo. Dermatology. 2023;239(6):919–925. doi:10.1159/000533353.
Management of the refractory vitiligo patient: current therapeutic strategies and future options. Front Immunol. 2023;14:1294919. doi:10.3389/fimmu.2023.1294919.
Liu J., Liu S., Guo M., Yong M., Hu Z. Clinical validation and study of stem cell transplantation in treatment of vitiligo. Arch Dermatol Res. 2023. doi:10.1007/s00403-023-02692-5
Downloads
Published
Issue
Section
How to Cite
